Overview

Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The aim of this pilot study is to assess the safety and preliminary efficacy of 5-ALA - SFC at doses up to 200 mg per day in subjects with type II diabetes.
Phase:
N/A
Details
Lead Sponsor:
SBI Pharmaceuticals Co, Ltd.
Treatments:
Aminolevulinic Acid